This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Epizyme Gestion

Gestion contrôle des critères 2/4

Informations clés

Grant Bogle

Directeur général

US$3.0m

Rémunération totale

Pourcentage du salaire du PDG	9.9%
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	2.3yrs
Durée moyenne du mandat des membres du conseil d'administration	10.2yrs

Mises à jour récentes de la gestion

Recent updates

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Aug 09

Epizyme Acquisition By Ipsen: CVR Value

Jul 05

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

May 16

Epizyme: Taking Advantage Of Recent Sell-Off

Nov 25

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Sep 14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Aug 10

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Feb 25

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Jan 16

Epizyme says Boehringer terminates collaboration agreement

Dec 24

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Dec 12

Epizyme Q3 2020 Earnings Preview

Nov 05

Analyse de la rémunération des PDG

Comment la rémunération de Grant Bogle a-t-elle évolué par rapport aux bénéfices de Epizyme?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2022	n/a	n/a	-US$208m
Mar 31 2022	n/a	n/a	-US$236m
Dec 31 2021	US$3m	US$299k	-US$251m
Sep 30 2021	n/a	n/a	-US$267m
Jun 30 2021	n/a	n/a	-US$257m
Mar 31 2021	n/a	n/a	-US$251m
Dec 31 2020	US$196k	n/a	-US$232m
Sep 30 2020	n/a	n/a	-US$222m
Jun 30 2020	n/a	n/a	-US$202m
Mar 31 2020	n/a	n/a	-US$192m
Dec 31 2019	US$309k	n/a	-US$173m

Rémunération vs marché: La rémunération totale de Grant ($USD 3.01M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 1.47M ).

Rémunération et revenus: La rémunération de Grant a augmenté alors que l'entreprise n'est pas rentable.

PDG

Grant Bogle (64 yo)

less than a year

Titularisation

US$3,011,807

Compensation

Mr. Grant C. Bogle has been Chief Executive Officer, President and Director at Epizyme, Inc. since August 9, 2021 and serves as Principal Financial Officer since November 1, 2021 and served as its Independ...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Grant Bogle	President	less than a year	US$3.01m	pas de données
Jeffery Kutok	Chief Scientific Officer	2.3yrs	US$2.86m	0.0080% $ 19.9k
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	pas de données	pas de données
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	pas de données	pas de données
Jerald Korn	Chief Operating Officer	less than a year	pas de données	pas de données
Joseph Beaulieu	Senior VP	4.1yrs	pas de données	0.0058% $ 14.3k
Craig West	Vice President of Investor Relations	no data	pas de données	pas de données
John Weidenbruch	Senior VP	no data	pas de données	pas de données
Tanja Weber	Chief Business Officer	3.6yrs	pas de données	pas de données
Mark De Rosch	Chief Regulatory Officer	2.8yrs	pas de données	pas de données
Rebecca Mehrwerth	Senior VP & Head of Commercial	less than a year	pas de données	pas de données
Christoph Diefenbach	Laboratory Manager of Research & Development	no data	pas de données	pas de données

2.3yrs

Durée moyenne de l'emploi

56.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de EPZM est considérée comme expérimentée (ancienneté moyenne 2.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Grant Bogle	President	2.9yrs	US$3.01m	pas de données
H. Horvitz	Co-Founder & Chairman of the Scientific Advisory Board	no data	pas de données	pas de données
Yi Zhang	Scientific Co-Founder & Member of The Scientific Advisory Board	no data	pas de données	pas de données
George Daley	Member of the Scientific Advisory Board	no data	pas de données	pas de données
David Mott	Independent Chairman	12.7yrs	US$370.00k	0.19% $ 474.0k
Carl Goldfischer	Independent Director	12.9yrs	US$350.00k	0.0030% $ 7.4k
Christopher Walsh	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Kenneth Bate	Independent Director	7.7yrs	US$330.94k	0% $ 0
Bruce Chabner	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Ronald Evans	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Joel Huff	Member of the Scientific Advisory Board	no data	pas de données	pas de données
Steven Henikoff	Member of the Scientific Advisory Board	no data	pas de données	pas de données

10.2yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la EPZM est chevronné et expérimenté ( 10.2 années d'ancienneté moyenne).

This company listing is no longer active

Epizyme Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Independent Chairman recently bought US$500k worth of stock

Independent Director recently bought US$60k worth of stock

Epizyme, Inc. Announces Executive Promotions

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Epizyme, Inc. Announces Executive Promotions

New 90-day low: US$10.34

Epizyme Q3 2020 Earnings Preview

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: US$11.52

New 90-day low - US$12.00

New 90-day low - US$12.13

First half earnings released

New 90-day low - US$13.84

Analyse de la rémunération des PDG